In the final episode of our PTSD series, Scott speaks with Dr. Jessica Maples Keller of Emory University about the future of psychedelic-assisted therapy for PTSD.
Emory has been studying MDMA and psilocybin in a clinical setting, with a focus on how these treatments might enhance evidence-based care like prolonged exposure therapy. Dr. Maples Keller explains how clinical trials are designed, why Schedule I status creates major barriers, what safety screening looks like, and why access and cost may become the next major challenge even if psychedelic-assisted treatments are eventually approved.
Then LTG(R) Walt Piatt, CEO of Wounded Warrior Project, returns to close out the series. He reflects on where the veteran community stands in addressing PTSD, what the VA and DoD are getting right and wrong, and whether the innovation happening across nonprofits, universities, and private organizations is a hopeful story about American civil society — or a sign that government systems are still moving too slowly.
This episode asks a simple question: if the future of PTSD treatment is already being built, why are so many veterans still waiting?
Guests:
Dr. Jessica Maples Keller — Associate Professor, Emory University School of Medicine
LTG(R) Walt Piatt — CEO, Wounded Warrior Project
Resources:
Emory Healthcare Veterans Program:
https://www.emoryhealthcare.org/centers-programs/veterans-program
For information about Emory psychedelic-assisted therapy studies:
PATstudy@emory.edu
MAPS — Multidisciplinary Association for Psychedelic Studies:
https://maps.org/
STRONG STAR:
https://www.strongstar.org/
Compass Pathways:
https://compasspathways.com/
Heroic Hearts Project:
https://heroicheartsproject.org/
Oregon Psilocybin Services:
https://www.oregon.gov/psilocybin
Australia Therapeutic Goods Administration — MDMA and psilocybin:
https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybine
Wounded Warrior Project:
https://www.woundedwarriorproject.org/
Powered by the WRKdefined Podcast Network.
Sponsors
